AstraZeneca jab benefits 'outweigh risks' but under-30s offered alternative
The benefits of the Oxford/AstraZeneca vaccine continue to outweigh any risks for most people, the UK medicines watchdog has said, as European regulators ruled that unusual blood clots were "very rare side effects" of the jab.
A review by the European Medicines Agency's safety committee concluded on Wednesday that "unusual blood clots with low blood platelets should be listed as very rare side effects" of the Oxford/AstraZeneca vaccine.
Emer Cooke, executive director of EMA, said its review "confirmed that the benefits of the AstraZeneca vaccine in preventing Covid-19 overall outweigh the risk of side effects," adding: "Vaccination is extremely important in helping us in the fight against Covid-19."
In the UK, the Medicines and Healthcare products Regulatory Agency (MHRA) said there were still huge benefits of the vaccine in preventing Covid-19 and serious disease.
However, due to a very small number of blood clots in younger people, those under the age of 30 will be offered Pfizer or Moderna instead.
Up to March 31, the MHRA has received 79 reports of blood clots accompanied by low blood platelet count, all in people who had their first dose of the vaccine.
Of these 79, a total of 19 people have died, although it has not been established what the cause was in every case.
The 79 cases occurred in 51 women and 28 men, aged from 18 to 79.
Of the 19 who died, three were under the age of 30, the MHRA said.
Some 14 cases of the 19 were cerebral venous sinus thrombosis (CVST), a specific type of clot that prevents blood from draining from the brain.
The other five cases were thrombosis.
The MHRA has concluded that the balance of risk for the vaccine is "very favourable for older people" but more finely balanced for younger groups.